The estimated Net Worth of Capital Partners Iii, Llc L... is at least $21.7 Million dollars as of 19 April 2022. Capital L owns over 1,355,000 units of Inozyme Pharma stock worth over $21,748,515 and over the last 5 years Capital sold INZY stock worth over $0.
Capital has made over 4 trades of the Inozyme Pharma stock since 2019, according to the Form 4 filled with the SEC. Most recently Capital bought 1,355,000 units of INZY stock worth $4,999,950 on 19 April 2022.
The largest trade Capital's ever made was buying 1,355,000 units of Inozyme Pharma stock on 19 April 2022 worth over $4,999,950. On average, Capital trades about 380,584 units every 127 days since 2019. As of 19 April 2022 Capital still owns at least 4,174,379 units of Inozyme Pharma stock.
You can see the complete history of Capital L stock trades at the bottom of the page.
Over the last 4 years, insiders at Inozyme Pharma have traded over $0 worth of Inozyme Pharma stock and bought 11,149,230 units worth $104,131,475 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Inozyme Pharma executives and independent directors trade stock every 46 days with the average trade being worth of $2,019,505. The most recent stock trade was executed by Douglas A Treco on 1 April 2024, trading 25,000 units of INZY stock currently worth $130,250.
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Inozyme Pharma executives and other stock owners filed with the SEC include: